Infinity Pharmaceuticals Provides Company Update and Second Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Tech selloff weighs down Wall Street as bond yields climb
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Francisco Partners to acquire Weave Communications for $650M
Infinity Pharma (INFI) Tops Q2 EPS by 3c
July 30, 2020 5:24 PM EDTInfinity Pharma (NASDAQ: INFI) reported Q2 EPS of ($0.16), $0.03 better than the analyst estimate of ($0.19).
We have made important clinical progress this quarter including the generation of early, but encouraging signals of clinical activity in the triple negative breast cancer cohort of MARIO-3, said Adelene Perkins, Chief Executive Officer and Chair of Infinity Pharmaceuticals. While these data are preliminary, we are... More
